PMC:7441777 / 604-743 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T3","span":{"begin":6,"end":9},"obj":"Body_part"},{"id":"T4","span":{"begin":20,"end":23},"obj":"Body_part"},{"id":"T5","span":{"begin":63,"end":66},"obj":"Body_part"}],"attributes":[{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma67095"}],"text":"D-19. RNA‐dependent RNA polymerase (RdRp) catalyzes SARS-CoV-2 RNA replication and hence, is an obvious target for antiviral drug design. I"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T7","span":{"begin":52,"end":60},"obj":"Disease"}],"attributes":[{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"D-19. RNA‐dependent RNA polymerase (RdRp) catalyzes SARS-CoV-2 RNA replication and hence, is an obvious target for antiviral drug design. I"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T9","span":{"begin":115,"end":129},"obj":"Chemical"},{"id":"T10","span":{"begin":115,"end":124},"obj":"Chemical"},{"id":"T11","span":{"begin":125,"end":129},"obj":"Chemical"}],"attributes":[{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_36044"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"D-19. RNA‐dependent RNA polymerase (RdRp) catalyzes SARS-CoV-2 RNA replication and hence, is an obvious target for antiviral drug design. I"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T1","span":{"begin":63,"end":78},"obj":"http://purl.obolibrary.org/obo/GO_0039703"}],"text":"D-19. RNA‐dependent RNA polymerase (RdRp) catalyzes SARS-CoV-2 RNA replication and hence, is an obvious target for antiviral drug design. I"}

{"project":"LitCovid-PubTator","denotations":[{"id":"44","span":{"begin":36,"end":40},"obj":"Gene"},{"id":"56","span":{"begin":52,"end":62},"obj":"Species"}],"attributes":[{"id":"A44","pred":"tao:has_database_id","subj":"44","obj":"Gene:43740578"},{"id":"A56","pred":"tao:has_database_id","subj":"56","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"D-19. RNA‐dependent RNA polymerase (RdRp) catalyzes SARS-CoV-2 RNA replication and hence, is an obvious target for antiviral drug design. I"}

{"project":"LitCovid-sentences","denotations":[{"id":"T10","span":{"begin":6,"end":137},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"D-19. RNA‐dependent RNA polymerase (RdRp) catalyzes SARS-CoV-2 RNA replication and hence, is an obvious target for antiviral drug design. I"}